Safety and Efficacy of Balloon Pulmonary Angioplasty in China
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese Pulmonary Vascular Disease Research Group
About this trial
Balloon pulmonary angioplasty (BPA) is a potential treatment for non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH).
The aim of this study was to evaluate the safety and efficacy of BPA in CTEPH patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA.
Eligibility criteria
Qualifiers
diagnosed with CTEPH according to ESC Guidelines (1) Mean PAP ≥ 25mmHg at rest; or if mean PAP < 25mmHg at rest, have exercise limitations from chronic thromboembolic disease (2)Abnormal ventilation perfusion lung scanning (VQ) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines
Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH
Not amenable to pulmonary endarterectomy
Willing to provide informed consent
Disqualifiers
Patients unwilling or unable to provide written consent for participation in the study.
Impossible to follow up.
Trial design
Treatments tested in this trial
- Balloon pulmonary angioplasty
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov